----item----
version: 1
id: {C4ED9060-BC5C-4C95-BC03-B93FCA912732}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/05/05/FDA OKs fluoroquinolone Avelox for plague
parent: {7EF2F9F0-FA16-460D-B72D-92BAE83627F5}
name: FDA OKs fluoroquinolone Avelox for plague
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 0b53d0a0-00a7-43bf-a4d7-5df376a5265b

----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 42

FDA OK's fluoroquinolone Avelox for plague
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 41

FDA OKs fluoroquinolone Avelox for plague
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 2140

<p>The FDA on 8 May gave its blessing to Merck to market Avelox (moxifloxacin), a fluoroquinolone antibacterial, as a treatment for plague, including pneumonic plague, which is a bacterial infection of the lungs, and septicemic plague, and infection of the blood. </p><p>The drug, which Merck licensed from Bayer HealthCare Pharmaceuticals, also is approved to prevent plague in adults.</p><p>Regulators noted that plague is extremely rare in most parts of the world, including the US.</p><p>Only about 1,000 to 2,000 cases of plague, which also includes bubonic, an infection of the lymph nodes, occur worldwide each year. </p><p>Plague can be spread to humans through bites from infected fleas, contact with infected animals or humans, or laboratory exposure. </p><p>The bacteria that causes plague, <i>Yersinia pestis</i>, is considered a biological threat agent that could potentially be used as a bioterrorism agent, regulators pointed out.</p><p>Avelox previously was approved in the US for adults 18 years or older to treat acute bacterial sinusitis, acute bacterial exacerbation of chronic bacterial exacerbation of chronic bronchitis, community-acquired pneumonia, complicated intra-abdominal infections and skin and skin structure infections &ndash; uncomplicated and complicated.</p><p>The FDA approved Avelox for plague under the agency's animal rule, which was created in 2002 to permit a drug's effectiveness to be demonstrated in animals when it is unethical or not feasible to conduct controlled clinical trials in humans.</p><p>Under the rule, which has been used rarely, a drug may be approved on the basis of adequate and well-controlled animal studies when the results establish the product is reasonably likely to produce clinical benefit in humans.</p><p>Avelox carries a <a href="http://www.scripintelligence.com/policyregulation/FDA-warns-of-rapid-permanent-nerve-damage-with-fluoroquinolones-345918" target="_new">black-box warning</a> about an increased risk of tendinitis and tendon rupture and worsening of muscle weakness in people with the neuromuscular disorder myasthenia gravis. </p><p><p><p><p><p><p><p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 268

<p>The FDA on 8 May gave its blessing to Merck to market Avelox (moxifloxacin), a fluoroquinolone antibacterial, as a treatment for plague, including pneumonic plague, which is a bacterial infection of the lungs, and septicemic plague, and infection of the blood. </p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 41

FDA OKs fluoroquinolone Avelox for plague
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150505T160000
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150505T160000
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150505T160000
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC028677
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 42

FDA OK's fluoroquinolone Avelox for plague
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{185C14A2-61E1-460C-96C2-EB0D8AB963B0}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 13

Headline News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

358199
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042343Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

0b53d0a0-00a7-43bf-a4d7-5df376a5265b
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042343Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
